Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
Study Details
Study Description
Brief Summary
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group 1 Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels. |
Biological: 24 valent pneumococcal conjugate vaccine
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
|
| Experimental: Group 2 Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels. |
Biological: 24 valent pneumococcal conjugate vaccine
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
|
| Experimental: Group 3 Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels. |
Biological: 24 valent pneumococcal conjugate vaccine
0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
|
| Active Comparator: Group 4 Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1. |
Biological: 20 valent pneumococcal conjugate vaccine
0.5 ml dose of PCV20 will be administered into the deltoid muscle at Day 1
|
Outcome Measures
Primary Outcome Measures
- Percentage of participants reporting solicited local reactions within 7 days after vaccination in each age group [7 days after vaccination]
Solicited local reactions included redness/erythema, swelling/induration, and pain at injection site
- Percentage of participants reporting solicited systemic events within 7 days after vaccination in each age group [7 days after vaccination]
Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain
- Percentage of participants reporting unsolicited adverse events (AE) in each age group [1 month after vaccination]
Percentage of participants with adverse events (AEs), serious adverse events (SAEs) in each age group
- Percentage of participants reporting SAEs and new onset of chronic illnesses (NOCI) [6 months after vaccination]
Percentage of participants with SAEs and NOCIs
Secondary Outcome Measures
- Percentage of participants with laboratory value abnormalities and/or potentially clinically significant laboratory values [1 month after vaccination]
Percentage of participants with potential laboratory abnormalities and clinically significant laboratory values
- 24 VAX-24 Pneumococcal serotype-specific opsonophagocytic assay (OPA) geometric mean titer (GMTs) [1 month after vaccination]
Antibody geometric mean titers as measured by OPA for the 24 pneumococcal serotypes in VAX-24
- 24 VAX-24 Pneumococcal serotype-specific IgG geometric mean concentration (GMCs) [1 month after vaccination]
Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female age 18 to 49 years (inclusive) for the Phase 1 group, or 50 to 64 years (inclusive) for the Phase 2 group at the time of enrollment into the study.
-
Able and willing to complete the informed consent process.
-
Available for clinical follow-up through the last study visit at 6 months after the study vaccination.
-
In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the investigator.
-
Screening laboratory values must be within the central laboratory normal limits prior to study enrollment. Minor abnormalities are considered acceptable if not clinically significant.
-
Willing to have blood samples collected, stored indefinitely, and used for research purposes.
-
Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process.
-
Negative pregnancy test (urine and serum) for women of childbearing potential.
Exclusion Criteria:
-
Previous pneumococcal disease (either confirmed or by self-reporting).
-
Previous receipt of a licensed or investigational pneumococcal vaccine.
-
Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.
-
Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Day 29.
-
Physical examination indicating any clinically significant medical condition.
-
Body Temperature > 38.0°C (> 100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled).
-
Seropositive to HIV, HCV, or HBsAg.
-
History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis.
-
Female who is breast-feeding or planning to become pregnant during study participation.
-
Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
-
Any other chronic or clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine.
-
Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent.
-
Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study.
-
Received systemic corticosteroids for ≥ 14 consecutive days and has not completed treatment ≤30 days prior to enrollment into the study.
-
Receiving immunosuppressive therapy.
-
History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CenExel RCA | Hollywood | Florida | United States | 33024 |
| 2 | Precision Clinical Research | Sunrise | Florida | United States | 33351 |
| 3 | Meridian Clinical Research | Savannah | Georgia | United States | 31406 |
| 4 | Velocity Clinical Research | Valparaiso | Indiana | United States | 46383 |
| 5 | Johnson County Clin-Trials | Lenexa | Kansas | United States | 66219 |
| 6 | Benchmark Research | Metairie | Louisiana | United States | 70006 |
| 7 | Alliance for Multispecialty Research | Kansas City | Missouri | United States | 64114 |
| 8 | Rochester Clinical Research | Rochester | New York | United States | 14609 |
| 9 | Acellacare of Wilmington | Wilmington | North Carolina | United States | 28401 |
| 10 | Velocity Clinical Research | Warwick | Rhode Island | United States | 02886 |
| 11 | Coastal Carolina Research | North Charleston | South Carolina | United States | 29405 |
| 12 | Benchmark Research | San Angelo | Texas | United States | 76904 |
| 13 | JBR Clinical Research | Salt Lake City | Utah | United States | 84107 |
Sponsors and Collaborators
- Vaxcyte, Inc.
Investigators
- Study Director: Clinical Development, Vaxcyte, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VAX24-101